[{"orgOrder":0,"company":"Yale Cancer Center","sponsor":"Alliance for Cancer Gene Therapy","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"MAEGI","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Yale Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale Cancer Center \/ Alliance for Cancer Gene Therapy","highestDevelopmentStatusID":"1","companyTruncated":"Yale Cancer Center \/ Alliance for Cancer Gene Therapy"}]

Find Clinical Drug Pipeline Developments & Deals by Yale Cancer Center

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : With this grant Sidi Chen, assistant professor at the Yale School of Medicine and member of Yale Cancer Center, will advance a versatile and highly scalable strategy he's been developing and calling MAEGI -- Multiplexed Activation of Endogenous Genes as...

                          Product Name : MAEGI

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 16, 2020

                          Lead Product(s) : MAEGI

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Alliance for Cancer Gene Therapy

                          Deal Size : $0.5 million

                          Deal Type : Funding

                          blank